Filing excerpt
In January 2026, we announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating tafasitamab and lenalidomide in combination with R-CHOP as a first-line therapy for patients with DLBCL.
Source: Autobound Signal API · 75 signals tracked for Incyte · updated
Get Incyte's live signals in Claude or ChatGPT, or by API
What changed at Incyte this week? Use Autobound signals for incyte.com.Following positive results from the frontMIND trial, Incyte will file for a major label expansion. This regulatory process is heavily data-driven and precedes a large-scale commercial effort, creating needs for regulatory information management and market access data platforms.
Filing excerpt
In January 2026, we announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating tafasitamab and lenalidomide in combination with R-CHOP as a first-line therapy for patients with DLBCL.
What this signalsFilings often name leadership changes, deals and spending plans.
sec-10kdataInvestmentGet every 10-K signal for Incyte and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Incyte this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/75f5fde0-8781-4399-a1c4-df93aa72bd5f returns this record as JSON. POST /v1/companies/enrich returns every signal for incyte.com.
{
"signal_id": "75f5fde0-8781-4399-a1c4-df93aa72bd5f",
"signal_type": "sec-10k",
"signal_subtype": "dataInvestment",
"detected_at": "2026-02-17T06:34:03.067+00:00",
"company": {
"name": "Incyte",
"domain": "incyte.com"
},
"data": {
"detail": "Following positive results from the frontMIND trial, Incyte will file for a major label expansion. This regulatory process is heavily data-driven and precedes a large-scale commercial effort, creating needs for regulatory information management and market access data platforms.",
"metrics": {
"timeframe": "current_year"
},
"summary": "Filing for new drug indication for tafasitamab in H1 2026 after positive Phase 3 trial.",
"excerpts": "In January 2026, we announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating tafasitamab and lenalidomide in combination with R-CHOP as a first-line therapy for patients with DLBCL.",
"relevance": 0.8,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htm",
"filing_date": "2026-02-10",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "Target for data vendors",
"signal_category": "technology"
}
}
curl https://signals.autobound.ai/v1/signals/75f5fde0-8781-4399-a1c4-df93aa72bd5f \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"incyte.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.